CD19 and CD20 are expressed on multiple differentiated B-lineage cells as well as malignant B cells, and represent attractive targets for CAR-T cell therapy in B-ALL and lymphoma. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.